Committee also accepted Braftovi combination, Ledaga and Zejula for use by NHS Scotland in May decisions
News
Positive CHMP opinion for self-administered Crysvita
Crysvita is used for the treatment of the rare metabolic bone disease X-linked hypophosphataemia (XLH)
Researchers find CD38-targeting drugs may show promise against prostate cancer
Researchers are initiating clinical trials to evaluate whether targeting the CD38 pathway can provide benefit for people with prostate cancer
WHO grants Sinopharm’s COVID-19 vaccine emergency approval
First COVID-19 jab developed by a non-Western company to gain this recommendation
AZ/Daiichi Sankyo’s datopotamab deruxtecan demonstrates ‘promising’ early results in TNBC
New data presented at the 2021 European Society of Medical Oncology (ESMO) Breast Cancer virtual congress
Vectura, Inspira team up to develop inhaled COVID-19 drug
The deal will see Vectura test Inspira’s inhaled IPX formulation candidates
Imfinzi, tremelimumab combo boosts survival in lung cancer
The POSEIDON trial is the first Phase III study to demonstrate an overall survival benefit with tremelimumab
Only one week left to enter the Patient Partnership Index 2021
The entry deadline is Friday May 14
UK launch for progressive multiple sclerosis mega-trial
It is hoped that the multi-armed Octopus trial will rapidly speed up development of new treatments
AZ’ Tagrisso first to win MHRA approval under Project Orbis
Decision brings the innovative treatment to early-stage lung cancer patients, helping to address unmet need in this setting
Communications Awards winner shares insight into the competition
Lucinda Sandon-Allum of Langland and winner in the 2020 Aspiring Communications Manager of the Year shares her competition highlights.
Alchemab to collaborate with AstraZeneca on prostate cancer research
Collaboration will aim to improve understanding of prostate cancer and identify novel antibodies for the disease
Preliminary NICE ‘no’ for Merck’s Bavencio
The cost regulator has rejecting funding the drug as maintenance treatment of advanced/metastatic urothelial cancer
EC clears GSK’s Benlysta for lupus nephritis
The drug is the only biologic treatment approved in Europe that is specifically designed to work in systemic lupus erythematosus and lupus nephritis
US supports waiving IP for COVID vaccines
MSF has applauded the move, but the IFPMA said the decision is “disappointing”
